Javascript must be enabled to continue!
Understanding Health Literacy Among Patients with Thalassemia: A Global Patient Survey by the Thalassemia Advocacy Advisory Council
View through CrossRef
Background: Thalassemia is a rare, under-recognized hereditary hemolytic anemia with a variable clinical presentation, resulting in a variety of symptoms and complications that can substantially impact patient health-related quality of life. Despite advances in the management of thalassemia, unmet needs remain in this diverse patient population. The Thalassemia Advocacy Advisory Council (AAC), an international group comprising patients, caregivers, advocacy organizations, and healthcare professionals (supported by Agios Pharmaceuticals) was launched to define and better understand the unmet needs of the thalassemia community, as well as to support improvement in patient outcomes and care. Following an initial assessment to understand priority areas, health literacy (ie, understanding of thalassemia, its complications, and treatment approaches) was identified as a key unmet need for patients with thalassemia. Subsequently, the results of an evidence audit of published literature and advocacy group/community-based research on health literacy in thalassemia further demonstrated unmet informational and educational needs, which informed key areas for exploration. Based on these findings, the Thalassemia AAC developed a patient survey, with the aim of better understanding the global community's perspectives and identifying strategies to potentially address patients' health literacy needs. Here, we describe the methodology of this global patient survey.
Methods: This initiative utilizes a bespoke, self-administered, approximately 12-15-minute survey developed by the Thalassemia AAC. Adults (aged ≥18 years) with a diagnosis of alpha- or beta-thalassemia are eligible to participate in this study, excluding those diagnosed with alpha- or beta-thalassemia trait or those who are currently enrolled in a clinical trial involving mitapivat (for example, ENERGIZE [NCT04770753] or ENERGIZE-T [NCT04770779]). All participants must provide informed consent before taking part in the survey. Approximately 105 participants from the Middle East (United Arab Emirates, Saudi Arabia, Qatar, Bahrain, Kuwait, Oman), Italy, USA, Greece, and Brazil are planned to be recruited via two recruitment streams: 1) a specialist survey recruitment agency, or 2) a patient advocacy organization network. The primary objective is to describe health literacy in patients with thalassemia; secondary objectives include studying barriers and motivational aspects that affect disease understanding and self-management, and how these survey findings compare with previously conducted research. The survey comprises six sections: (i) Screening (including patient age and clinical characteristics); (ii) Demographics (including optional questions), to better understand the patient profile; (iii) Channels and formats, to understand where respondents search for information and their preferred content format; (iv) Disease knowledge, to collect information on disease understanding; (v) Challenges and barriers, to understand what drives the patient to seek a greater understanding and self-management of their disease; and (vi) Motivators, to uncover any positive external factors that influence the patient to seek an increased understanding and self-management of their disease. Participants complete the survey online and data are captured electronically. Survey responses will be summarized descriptively as number and percentage for categorical variables, and mean with standard deviation or median with interquartile range for continuous variables. Qualitative, free text responses will be reviewed and categorized. A limitation of this survey is that its questions are bespoke and have not been validated.
Results: The survey is in progress and available results are currently being analyzed.
Conclusions: The Thalassemia AAC identified health literacy as a key unmet need for patients with thalassemia. This global patient survey will provide insight into the current state of health literacy (ie, knowledge of thalassemia, its complications, and treatment approaches) in the patient community, to support future improvement of thalassemia patient outcomes and care.
Title: Understanding Health Literacy Among Patients with Thalassemia: A Global Patient Survey by the Thalassemia Advocacy Advisory Council
Description:
Background: Thalassemia is a rare, under-recognized hereditary hemolytic anemia with a variable clinical presentation, resulting in a variety of symptoms and complications that can substantially impact patient health-related quality of life.
Despite advances in the management of thalassemia, unmet needs remain in this diverse patient population.
The Thalassemia Advocacy Advisory Council (AAC), an international group comprising patients, caregivers, advocacy organizations, and healthcare professionals (supported by Agios Pharmaceuticals) was launched to define and better understand the unmet needs of the thalassemia community, as well as to support improvement in patient outcomes and care.
Following an initial assessment to understand priority areas, health literacy (ie, understanding of thalassemia, its complications, and treatment approaches) was identified as a key unmet need for patients with thalassemia.
Subsequently, the results of an evidence audit of published literature and advocacy group/community-based research on health literacy in thalassemia further demonstrated unmet informational and educational needs, which informed key areas for exploration.
Based on these findings, the Thalassemia AAC developed a patient survey, with the aim of better understanding the global community's perspectives and identifying strategies to potentially address patients' health literacy needs.
Here, we describe the methodology of this global patient survey.
Methods: This initiative utilizes a bespoke, self-administered, approximately 12-15-minute survey developed by the Thalassemia AAC.
Adults (aged ≥18 years) with a diagnosis of alpha- or beta-thalassemia are eligible to participate in this study, excluding those diagnosed with alpha- or beta-thalassemia trait or those who are currently enrolled in a clinical trial involving mitapivat (for example, ENERGIZE [NCT04770753] or ENERGIZE-T [NCT04770779]).
All participants must provide informed consent before taking part in the survey.
Approximately 105 participants from the Middle East (United Arab Emirates, Saudi Arabia, Qatar, Bahrain, Kuwait, Oman), Italy, USA, Greece, and Brazil are planned to be recruited via two recruitment streams: 1) a specialist survey recruitment agency, or 2) a patient advocacy organization network.
The primary objective is to describe health literacy in patients with thalassemia; secondary objectives include studying barriers and motivational aspects that affect disease understanding and self-management, and how these survey findings compare with previously conducted research.
The survey comprises six sections: (i) Screening (including patient age and clinical characteristics); (ii) Demographics (including optional questions), to better understand the patient profile; (iii) Channels and formats, to understand where respondents search for information and their preferred content format; (iv) Disease knowledge, to collect information on disease understanding; (v) Challenges and barriers, to understand what drives the patient to seek a greater understanding and self-management of their disease; and (vi) Motivators, to uncover any positive external factors that influence the patient to seek an increased understanding and self-management of their disease.
Participants complete the survey online and data are captured electronically.
Survey responses will be summarized descriptively as number and percentage for categorical variables, and mean with standard deviation or median with interquartile range for continuous variables.
Qualitative, free text responses will be reviewed and categorized.
A limitation of this survey is that its questions are bespoke and have not been validated.
Results: The survey is in progress and available results are currently being analyzed.
Conclusions: The Thalassemia AAC identified health literacy as a key unmet need for patients with thalassemia.
This global patient survey will provide insight into the current state of health literacy (ie, knowledge of thalassemia, its complications, and treatment approaches) in the patient community, to support future improvement of thalassemia patient outcomes and care.
Related Results
Understanding health literacy among patients with thalassemia: Results from a global patient survey by the Thalassemia Advocacy Advisory Council
Understanding health literacy among patients with thalassemia: Results from a global patient survey by the Thalassemia Advocacy Advisory Council
Abstract
Introduction: Despite advances in the management of thalassemia, a rare and under-recognized hereditary anemia,...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Investigating Health Literacy in Thalassemia: Founding a Patient-Led Research Approach
Investigating Health Literacy in Thalassemia: Founding a Patient-Led Research Approach
Background:
Thalassemia is a hereditary hemolytic anemia (HHA) with a variable phenotype and clinical severity, and constantly changing demographic profile. Despite ...
Comprehensive analysis of a-and b-thalassemia genotypes and hematologic phenotypes
Comprehensive analysis of a-and b-thalassemia genotypes and hematologic phenotypes
Background: Guizhou Province is an area with high incidence of thalassemia. However, there are few large-sample studies on the correlation between genotypes and phenotypes in Guizh...
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
Thalassemia Phenotypes and Associated Mortality among Yemeni Patients: A Single-Center Retrospective Analysis
Thalassemia Phenotypes and Associated Mortality among Yemeni Patients: A Single-Center Retrospective Analysis
Objective: To retrospectively analyze thalassemia phenotypes and associated mortality among Yemeni patients seeking healthcare in Sana’a city, Yemen.
Methods: This retrospect...
Thalassemia Phenotypes and Associated Mortality among Yemeni Patients: A Single-Center Retrospective Analysis
Thalassemia Phenotypes and Associated Mortality among Yemeni Patients: A Single-Center Retrospective Analysis
Objective: To retrospectively analyze thalassemia phenotypes and associated mortality among Yemeni patients seeking healthcare in Sana’a city, Yemen.
Methods: This retrospect...
The Molecular Basis of Alpha-Thalassemia in the Qatari Pediatric Population
The Molecular Basis of Alpha-Thalassemia in the Qatari Pediatric Population
BackgroundAnemia is the most common hematologic abnormality that a pediatrician encounters in clinical practice. Alpha-Thalassemia (a-thal) is widely reported in the Arabian Penins...

